GLOSSARY: Biosimilars

Biosimilars, also referred to as Follow-on Biologics, is a term used to describe officially-approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Biosimilars are also referred to as subsequent entry biologics (SEBs) in Canada. Similar biological medicinal products are often called biosimilars.